Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection

The Journal of Infection
Oscar MurilloJavier Ariza

Abstract

The knowledge about efficacy of linezolid alone or in combination with rifampin in device infections is limited. We test their in vitro and in vivo efficacy in a rat model of foreign-body infection by methicillin-susceptible S. aureus. In vitro studies for logarithmic and stationary bacteria were performed. In vivo efficacy (decrease in bacterial counts in tissue cage fluid) was evaluated at: (i) after 7-day therapy (groups: linezolid, cloxacillin, rifampin, linezolid-rifampin and cloxacillin-rifampin); and (ii) after 10-day therapy (groups: rifampin and linezolid-rifampin). After 7-day therapy all groups were significantly better than controls; linezolid (Delta log cfu/ml: -0.59, no resistant strains) and cloxacillin (-0.85) were the least effective therapy; linezolid was significantly less active (P<0.05) than rifampin (-1.22, resistance 90%), cloxacillin-rifampin (-1.3) and linezolid-rifampin (-1.14). After 10-day therapy linezolid-rifampin was the most effective treatment (Delta log -1.44, no resistance, P<0.05); in contrast, rifampin resulted ineffective (Delta log 0.1) due to the growth of resistant strains (100%). Linezolid alone showed moderate efficacy, whereas its combination with rifampin prevented the emergence of r...Continue Reading

References

Jun 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A F WidmerW Zimmerli
Dec 1, 1982·Antimicrobial Agents and Chemotherapy·D M RyanS M Harding
Jun 1, 1993·Antimicrobial Agents and Chemotherapy·M DrancourtD Raoult
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
May 21, 1999·Science·J W CostertonE P Greenberg
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J W ChienR A Salata
Jul 21, 2001·Lancet·P S Stewart, J W Costerton
Oct 16, 2004·The New England Journal of Medicine·Werner ZimmerliPeter E Ochsner
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Matteo BassettiDante Bassetti
Apr 6, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A SorianoJ Mensa

❮ Previous
Next ❯

Citations

Sep 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jaime Lora-TamayoUNKNOWN REIPI Group for the Study of Prosthetic Infection
Nov 17, 2009·The Journal of Antimicrobial Chemotherapy·J R Samuel, F K Gould
May 6, 2011·The Journal of Antimicrobial Chemotherapy·F Kate Gould
May 4, 2012·The Journal of Antimicrobial Chemotherapy·Federico PeaMario Furlanut
Feb 27, 2010·Anesthesia and Analgesia·Marco MercieriRoberto Arcioni
Sep 13, 2011·Expert Review of Anti-infective Therapy·Javier Cobo, Jose Luis Del Pozo
Mar 17, 2011·Expert Opinion on Pharmacotherapy·Jaime Esteban, José Cordero-Ampuero
Jan 13, 2015·Expert Review of Anti-infective Therapy·Dolors Rodríguez-PardoBenito Almirante

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.